Keros Therapeutics, Inc.(KROS)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

KROS Keros Therapeutics, Inc.

交易中 12-23 12:47:52 EST

17.16

+0.13

+0.76%

最高17.45	最低16.98	成交量38.04万
今开17.02	昨收17.03	日振幅2.76%
总市值6.95亿	流通市值6.07亿	总股本4,051万
成交额652.45万	换手率1.08%	流通股本3,537万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"KROS","market":"US","secType":"STK","nameCN":"Keros Therapeutics, Inc.","latestPrice":17.16,"timestamp":1734976072250,"preClose":17.03,"halted":0,"volume":380376,"delay":0,"floatShares":35370900,"shares":40507409,"eps":-5.208784,"marketStatus":"交易中","marketStatusCode":2,"change":0.13,"latestTime":"12-23 12:47:52 EST","open":17.02,"high":17.45,"low":16.98,"amount":6524491.390992,"amplitude":0.027598,"askPrice":17.17,"askSize":200,"bidPrice":17.13,"bidSize":31,"shortable":3,"etf":0,"ttmEps":-5.208784,"exchange":"NASDAQ","tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1734987600000},"adr":0,"listingDate":1586318400000,"adjPreClose":17.03,"preHourTrading":{"tag":"盘前","latestPrice":17.65,"preClose":17.03,"latestTime":"09:28 EST","volume":3681,"amount":62233.452269999994,"timestamp":1734964102715},"postHourTrading":{"tag":"盘后","latestPrice":17.01,"preClose":17.03,"latestTime":"19:39 EST","volume":93595,"amount":1593944.14,"timestamp":1734741584491},"volumeRatio":0.386018,"impliedVol":0.8447,"impliedVolPercentile":0.8088},"requestUrl":"/m/hq/s/KROS","defaultTab":"news","newsList":[{"id":"2492205158","title":"Keros Therapeutics, Inc.盘中异动 大幅跳水5.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2492205158","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492205158?lang=zh_cn&edition=full","pubTime":"2024-12-19 03:30","pubTimestamp":1734550217,"startTime":"0","endTime":"0","summary":"北京时间2024年12月19日03时30分，Keros Therapeutics, Inc.股票出现异动，股价快速下跌5.06%。Keros Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为1.61%。Keros Therapeutics, Inc.公司简介：Keros Therapeutics Inc 是一家临床阶段的生物制药公司，专注于发现、开发和商业化新的治疗方法，用于医疗需求未得到满足的患有血液病、肺病和心血管疾病的患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024121903301795ea590d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024121903301795ea590d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["KROS","BK4139","LENZ"],"gpt_icon":0},{"id":"2492617876","title":"BUZZ-古根海姆将 Keros Therapeutics 的评级下调至 \"中性\"。","url":"https://stock-news.laohu8.com/highlight/detail?id=2492617876","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492617876?lang=zh_cn&edition=full","pubTime":"2024-12-17 01:27","pubTimestamp":1734370022,"startTime":"0","endTime":"0","summary":"12月16日 -  ** 券商Guggenheim将药物开发商Keros Therapeutics KROS.O的评级从 \"买入 \"下调至 \"中性\"；取消对该股的评级，之前的评级为102美元 ** 周四，该公司在一项中期研究中暂停了更高剂量的高血压试验性治疗药物 \"cibotercept \" ，此前有报告称该药物出现了不良反应，经纪公司对此表示 \"惊讶 \"和 \"失望\"。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241216:nL4T3NH19G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MRK","KROS"],"gpt_icon":0},{"id":"2491653569","title":"美国研究综述-亚马逊、福特、Netflix","url":"https://stock-news.laohu8.com/highlight/detail?id=2491653569","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491653569?lang=zh_cn&edition=full","pubTime":"2024-12-16 15:34","pubTimestamp":1734334480,"startTime":"0","endTime":"0","summary":"美国研究综述-亚马逊、福特、Netflix路透12月16日 - 华尔街证券分析师周一调整了对亚马逊、福特和 Netflix 等多家美国上市公司的评级和目标价。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241216:nL4T3NH0G5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VAC","SLG","WH","HLT","CNO","MET","AFG","KROS","LNG","AIG","SIVBQ","OKTA","CBSH","PFG","ALL","AR","RRC","AMZN","GNW","CQP","GL","H","SKWD","BLFS","CZR","EXE","NFLX","MGM","EDIT","INCY","FFIC","TNL","VIK","MAR","PRI","LVS","SAM","SIGI","CCL","CRBG","NCLH","RCL","RLI","BKV","HGV","DOW"],"gpt_icon":1},{"id":"1119451677","title":"异动解读 | Keros Therapeutics, Inc.(KROS)盘中大涨7.54%,成药研发进展顺利推升预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1119451677","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1119451677?lang=zh_cn&edition=full","pubTime":"2024-12-13 22:34","pubTimestamp":1734100462,"startTime":"0","endTime":"0","summary":"Keros Therapeutics, Inc.(KROS)股价今日盘中出现大涨,引起了市场广泛关注。从目前公开消息来看,这与该公司的药物研发取得进展有关。\n\nKeros是一家临床阶段生物制药公司,专注于开发治疗血液病、肺病和心血管疾病的新疗法。其候选产品KER-050正处于治疗骨髓增生异常综合征(MDS)和骨髓纤维化患者的临床试验阶段,有望解决这些患者的贫血和血小板减少等症状。\n\n虽然公开消息中没有提及KER-050最新进展,但业内分析普遍预计其研发进程顺利,有望在不久后获批上市,满足临床需求空白。这使投资者对Keros未来发展前景抱有更高预期,成为推动股价大涨的主因。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"异动解读 | Keros Therapeutics, Inc.(KROS)盘中大涨7.54%,成药研发进展顺利推升预期","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["KROS"],"gpt_icon":0},{"id":"2491373027","title":"Keros Therapeutics, Inc.盘中异动 大幅上涨5.81%","url":"https://stock-news.laohu8.com/highlight/detail?id=2491373027","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491373027?lang=zh_cn&edition=full","pubTime":"2024-12-13 22:31","pubTimestamp":1734100299,"startTime":"0","endTime":"0","summary":"北京时间2024年12月13日22时31分，Keros Therapeutics, Inc.股票出现波动，股价急速拉升5.81%。Keros Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.16%。Keros Therapeutics, Inc.公司简介：Keros Therapeutics Inc 是一家临床阶段的生物制药公司，专注于发现、开发和商业化新的治疗方法，用于医疗需求未得到满足的患有血液病、肺病和心血管疾病的患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241213223139ab758c54&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241213223139ab758c54&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LENZ","KROS"],"gpt_icon":0},{"id":"2491358136","title":"BUZZ--美国股票走势-星座能源、好市多、ServiceTitan","url":"https://stock-news.laohu8.com/highlight/detail?id=2491358136","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491358136?lang=zh_cn&edition=full","pubTime":"2024-12-13 02:39","pubTimestamp":1734028759,"startTime":"0","endTime":"0","summary":"** 华纳兄弟发现公司  : BUZZ - 因计划分拆电视和流媒体部门而上涨   ** Middleby Corp   : BUZZ - 因Jefferies将其评级下调至 \"持有\"，并下调预期收益率而下跌。** MMTec Inc   : BUZZ - 在宣布反向股票分割后下跌。** Financial Institutions Inc   : BUZZ - 在1亿美元股票发行定价后下跌。** ServiceTitan Inc   : BUZZ - 在纳斯达克的首次亮相中飙升近 50%。** Hut 8 Corp   : BUZZ - 跳涨，JonesResearch以 \"买入 \"为初始评级。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CMCSA","KROS","NDSN","QLD",".IXIC","ROK","RCL","USJW.SI","CNP","FISI","LOVE","WBD","CNC","TTAN","UDOW","NUE","LQDT","OXM",".SPX","TQQQ","CCL","JILL","159945","CEG","DTE","ACI","TMUS","CMS","STLD","NCLH","SHOT","USAW.SI","MTC","ORA","COST","OTIS","MMC","ADBE","NVIW.SI","MNQmain",".DJI","DUK","MDLZ","ALGT","KGS"],"gpt_icon":1},{"id":"2490386483","title":"BUZZ--美国股票走势-Riot Platforms、Archer、J.Jill","url":"https://stock-news.laohu8.com/highlight/detail?id=2490386483","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490386483?lang=zh_cn&edition=full","pubTime":"2024-12-12 23:42","pubTimestamp":1734018141,"startTime":"0","endTime":"0","summary":".N美国东部时间10:30，道琼斯工业平均指数.DJI下跌0.09%，报44,110.17点；标普500指数.SPX下跌0.18%，报6,073.42点；纳斯达克综合指数.IXIC下跌0.28%，报19,979.74点。标准普尔 500 指数.PG.INX涨幅前三名是： ** 华纳兄弟发现公司WBD.OQ，上涨 12.7. ** 大都会人寿MET.N，上涨 4.7 标准普尔 500 指数.PL.INX跌幅前三名： ** Adobe Inc ADBE.OQ，下跌 12.5. nL4N3ND0YY  ** 华纳兄弟发现公司WBD.O:BUZZ - 因计划分拆电视和流媒体部门而上涨 nL4N3ND10C  ** Middleby Corp MIDD.O:BUZZ - 因Jefferies将其评级下调至 \"持有\"，并下调预期收益率而下滑。nL4N3ND10Q  ** MMTec Inc MTC.O:BUZZ - 在宣布反向股票分割后下跌。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241212:nL4S3ND17P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BNED","MDLZ","RIOT","CMCSA","CHWY","CIEN","CMS","TMUS","BN","BEPC","MTC","MIDD","DTE","KGS","ORA","TPL","KROS","ROK","BURL","LOVE","MET","BK4187","PALI","DDD","BPT","CNP","ACI","SFHG","SRFM","TSYW.SI","ABT","ALGT","KR","FISI","ACHR","OXM","DUK","TRVI","WBD","ADBE","JILL","CNC","MMC","SPGC","CZR","NDSN","GD"],"gpt_icon":1},{"id":"2490494387","title":"BUZZ-Keros Therapeutics 因安全性问题停止试验用药，创历史新低","url":"https://stock-news.laohu8.com/highlight/detail?id=2490494387","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490494387?lang=zh_cn&edition=full","pubTime":"2024-12-12 23:09","pubTimestamp":1734016175,"startTime":"0","endTime":"0","summary":" (更新)    12月12日 - ** 药物开发商Keros Therapeutics   股价下跌约77%，跌至2020年4月纳斯达克上市以来的 最低水平 15.96美元。** KROS表示，由于心脏周围液体积聚，已停止  每公斤 3.0毫克和  每公斤 4.5毫克剂量的高血压治疗药物的中期研究。** 1.5毫克/公斤组的用药将在独立监督委员会进行风险效益审查后继续进行 - KROS** 公司已向美国 FDA 发出通知，预计将于 2025 年第二季度提交所有治疗组的数据 - KROS** 包括本交易日的走势在内，该股今年已累计下跌58.6","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","KROS","BK4139"],"gpt_icon":0},{"id":"2490382926","title":"Keros Therapeutics, Inc.盘中异动 早盘快速下跌72.91%","url":"https://stock-news.laohu8.com/highlight/detail?id=2490382926","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490382926?lang=zh_cn&edition=full","pubTime":"2024-12-12 22:31","pubTimestamp":1734013898,"startTime":"0","endTime":"0","summary":"北京时间2024年12月12日22时31分，Keros Therapeutics, Inc.股票出现异动，股价急速下跌72.91%。Keros Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.10%。Keros Therapeutics, Inc.公司简介：Keros Therapeutics Inc 是一家临床阶段的生物制药公司，专注于发现、开发和商业化新的治疗方法，用于医疗需求未得到满足的患有血液病、肺病和心血管疾病的患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241212223138a1e95071&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241212223138a1e95071&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["KROS","LENZ","BK4139"],"gpt_icon":0},{"id":"2490389286","title":"BUZZ--美国股票走势-Chewy、Centene、通用动力公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2490389286","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490389286?lang=zh_cn&edition=full","pubTime":"2024-12-12 22:08","pubTimestamp":1734012481,"startTime":"0","endTime":"0","summary":"由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241212:nL4S3ND10V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1003077747.HKD","LU0266013472.USD","BK4559","LU2477742899.HKD","IE00BK4W5L77.USD","KROS","LOVE","SGXZ99366536.SGD","TSYW.SI","KGS","LU1145028129.USD","ORA","ACI","DTE","LU1244550221.USD","LU1429558221.USD","CMCSA","LU0648001328.SGD","GD","LU0557290698.USD","BK4099","ALGT","LU2346227817.USD","LU2756315318.SGD","DUK","OXM","BK4515","BK4212","IE000M9KFDE8.USD","CNC","NDSN","LU0289961442.SGD","CMS","LU0943347566.SGD","LU0106261372.USD","MDLZ","CNP","ADBE","LU1878469433.USD","LU1861220033.SGD","LU1621767810.EUR","MMC","KR","BURL","CIEN","ABT","CHWY","LU0154245756.USD"],"gpt_icon":1},{"id":"2490021998","title":"BUZZ--美国股票走势-Adobe、Nordson、Keros Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2490021998","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490021998?lang=zh_cn&edition=full","pubTime":"2024-12-12 20:14","pubTimestamp":1734005674,"startTime":"0","endTime":"0","summary":".N ** Adobe Inc ADBE.O： BUZZ - 因下调25财年收入预期而下滑，PT下调 nL4N3ND0ML  ** Nordson Corp NDSN.O： BUZZ - 预测 2025 财年销售额和利润低于预期，股价下跌 nL4N3ND0R0  ** Keros Therapeutics Inc KROS.O： BUZZ--因安全性问题停止试验用药而暴跌 nL4N3ND0RU (为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241212:nL4S3ND0V1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4023","LU2317271919.USD","LU1366333091.USD","LU2125154935.USD","LU2125154778.USD","LU1674673428.USD","LU0889566641.SGD","LU2089283258.USD","LU2210150020.SGD","KROS","SGXZ51526630.SGD","LU0868494708.USD","LU2357305700.SGD","LU2236285917.USD","LU1720051108.HKD","LU0234570918.USD","LU0889565833.HKD","LU0557290698.USD","LU0861579265.USD","BK4554","BK4566","LU1548497426.USD","IE0009356076.USD","LU0170899867.USD","BK4567","NDSN","LU2237438978.USD","LU0942090050.USD","LU1803068979.SGD","LU0792757196.USD","LU1633808545.USD","LU0157215616.USD","LU0289961442.SGD","LU0109392836.USD","LU0234572021.USD","BK4585","ADBE","LU0320765059.SGD","LU1712237335.SGD","BK4534","LU0061474960.USD","LU1674673691.USD","BK4161","LU0069063385.USD","LU2095319765.USD","BK4527","LU0198837287.USD","LU0006306889.USD","LU0082616367.USD","LU1778281490.HKD"],"gpt_icon":1},{"id":"2490809087","title":"Keros Therapeutics在安全性审查后停止血压治疗用药","url":"https://stock-news.laohu8.com/highlight/detail?id=2490809087","media":"路透中文","labels":["event"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490809087?lang=zh_cn&edition=full","pubTime":"2024-12-12 19:31","pubTimestamp":1734003095,"startTime":"0","endTime":"0","summary":"更新版 1-Keros Therapeutics在安全性审查后停止血压治疗用药第 2 段增加了股票，第 3-5 段增加了详细信息路透12月12日 - Keros Therapeutics KROS.O周四表示，基于安全性审查，该公司已自愿停止在一项中期研究中使用其 3.0毫克 和4.5毫克剂量的高血压治疗药物。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241212:nL4T3ND0SF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KROS","BK4139"],"gpt_icon":0},{"id":"2490809708","title":"BUZZ-Keros Therapeutics公司因安全性问题停止试验用药而暴跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2490809708","media":"路透中文","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490809708?lang=zh_cn&edition=full","pubTime":"2024-12-12 19:29","pubTimestamp":1734002974,"startTime":"0","endTime":"0","summary":"BUZZ-Keros Therapeutics公司因安全性问题停止试验用药而暴跌12月12日 -  ** 药物开发商Keros Therapeutics KROS.O股价盘前下跌约71%至20美元 ** KROS表示，由于心脏周围出现积液，公司已停止了一项中期研究中3.0毫克和4.5毫克剂量的高血压治疗药物的给药。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241212:nL4T3ND0S0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KROS"],"gpt_icon":0},{"id":"2490880938","title":"Keros Therapeutics 在安全性审查后自愿停止血压治疗药物的剂量投放","url":"https://stock-news.laohu8.com/highlight/detail?id=2490880938","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490880938?lang=zh_cn&edition=full","pubTime":"2024-12-12 19:16","pubTimestamp":1734002199,"startTime":"0","endTime":"0","summary":"Keros Therapeutics 在安全性审查后自愿停止血压治疗药物的剂量投放路透12月12日 - Keros Therapeutics KROS.O周四表示，根据安全性审查结果，该公司已自愿停止了一项中期研究中3.0毫克(mg) 和4.5毫克剂量的高血压治疗药物的给药。 (为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241212:nL4S3ND0R5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KROS","BK4139"],"gpt_icon":0},{"id":"2488249239","title":"嗡嗡声--美国股票走势-PSQ Holdings、Core Scientific、Keros","url":"https://stock-news.laohu8.com/highlight/detail?id=2488249239","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488249239?lang=zh_cn&edition=full","pubTime":"2024-12-04 02:41","pubTimestamp":1733251314,"startTime":"0","endTime":"0","summary":"** Credo Technology Group Holding Ltd   : BUZZ - 因第二季度销售额超出预期而大涨   ** Janux Therapeutics Inc   : BUZZ - 因癌症药物的早期数据超出预期而飙升。** Core Scientific Inc   : BUZZ - 在扩大 5.5 亿美元可转换债券发行规模后上涨   ** Keros Therapeutics Inc   : BUZZ - 与武田达成血癌药物许可协议后上涨   ** AT&T Inc   : BUZZ - 在实施扩张计划和提高指导后创下 3 年半新高   ** Rio Tinto PLC   ：** BHP Group Ltd   ：** Southern Copper Corp   ：** Freeport-McMoRan Inc   : BUZZ - 铜矿企业因美元走软而上涨   ** Avadel Pharmaceuticals PLC   : BUZZ - 在首席商务官辞","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":[".SPX","JANX","ZS","MP","ROIV","NEM","TRGP","DXD","KR","CORZ","TERN","AXON","EQT","LYV","BLK","CVX","INTC","PSQH","KROS","UDOW","SCCO","X","AVDL","CUZ","OLLI","SDOW","T","DECK","CTRN","CHRS","DDM","FDX","DOG","DJX","CPNG","ADM","AZO","FCX","MOH","JBGS",".DJI","FDN",".IXIC","LTRN","XOM"],"gpt_icon":1},{"id":"2488422509","title":"BUZZ-与武田签订血癌药物许可协议后，Keros 公司业绩上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2488422509","media":"路透中文","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488422509?lang=zh_cn&edition=full","pubTime":"2024-12-03 23:56","pubTimestamp":1733241413,"startTime":"0","endTime":"0","summary":"12月3日 -  ** 药物开发商Keros TherapeuticsKROS.O股价上涨3.6%至58.78美元 ** KROS表示，它与武田4502.T就实验药物elritercept达成了全球许可协议 。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241203:nL3T3N419K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KROS","BK4139"],"gpt_icon":0},{"id":"2488947684","title":"Keros Therapeutics, Inc.盘中异动 急速拉升5.08%报59.61美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2488947684","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488947684?lang=zh_cn&edition=full","pubTime":"2024-12-03 23:55","pubTimestamp":1733241328,"startTime":"0","endTime":"0","summary":"北京时间2024年12月03日23时55分，Keros Therapeutics, Inc.股票出现异动，股价快速上涨5.08%。Keros Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.48%。Keros Therapeutics, Inc.公司简介：Keros Therapeutics Inc 是一家临床阶段的生物制药公司，专注于发现、开发和商业化新的治疗方法，用于医疗需求未得到满足的患有血液病、肺病和心血管疾病的患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024120323552998e51fcd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024120323552998e51fcd&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","KROS","LENZ"],"gpt_icon":0},{"id":"2485295717","title":"Keros Therapeutics, Inc.盘中异动 大幅拉升5.22%","url":"https://stock-news.laohu8.com/highlight/detail?id=2485295717","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485295717?lang=zh_cn&edition=full","pubTime":"2024-11-23 00:45","pubTimestamp":1732293924,"startTime":"0","endTime":"0","summary":"北京时间2024年11月23日00时45分，Keros Therapeutics, Inc.股票出现异动，股价快速拉升5.22%。Keros Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.71%。Keros Therapeutics, Inc.公司简介：Keros Therapeutics Inc 是一家临床阶段的生物制药公司，专注于发现、开发和商业化新的治疗方法，用于医疗需求未得到满足的患有血液病、肺病和心血管疾病的患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024112300452598e4432f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024112300452598e4432f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LENZ","KROS"],"gpt_icon":0},{"id":"2484893229","title":"Keros Therapeutics, Inc.盘中异动 临近收盘股价大跌5.07%报53.75美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2484893229","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484893229?lang=zh_cn&edition=full","pubTime":"2024-11-19 04:50","pubTimestamp":1731963000,"startTime":"0","endTime":"0","summary":"北京时间2024年11月19日04时50分，Keros Therapeutics, Inc.股票出现波动，股价快速跳水5.07%。截至发稿，该股报53.75美元/股，成交量43.8202万股，换手率1.08%，振幅5.65%。Keros Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.15%。Keros Therapeutics, Inc.公司简介：Keros Therapeutics Inc 是一家临床阶段的生物制药公司，专注于发现、开发和商业化新的治疗方法，用于医疗需求未得到满足的患有血液病、肺病和心血管疾病的患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024111904500198e43569&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024111904500198e43569&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LENZ","KROS"],"gpt_icon":0},{"id":"2483587286","title":"BUZZ-奥本海默称默克公司对 Winrevair 的谨慎接受为竞争对手提供了机会","url":"https://stock-news.laohu8.com/highlight/detail?id=2483587286","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483587286?lang=zh_cn&edition=full","pubTime":"2024-11-14 20:49","pubTimestamp":1731588586,"startTime":"0","endTime":"0","summary":"BUZZ-奥本海默称默克公司对 Winrevair 的谨慎接受为竞争对手提供了机会11月14日 -  ** 券商奥本海默称，鉴于默克公司的MRK.N疗法Winrevair在治疗一种罕见肺病方面的谨慎吸收，该疗法存在竞争机会。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241114:nL4S3ML1AE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B2B36J28.USD","LU1066051225.USD","LU1093756168.USD","LU0265550359.USD","KROS","LU1037948897.HKD","LU0265550946.USD","LU1989772923.USD","GOSS","SG9999014542.SGD","LU1585245621.USD","IE00B4R5TH58.HKD","LU1023059063.AUD","LU1941712264.USD","LU0266013472.USD","IE00BJT1NW94.SGD","LU1934455863.HKD","LU1934455194.USD","LU1974910355.USD","BK4585","BK4559","BK4139","LU1989772840.SGD","IE0009355771.USD","LU1066053197.SGD","LU0289739699.SGD","LU1037948541.HKD","BK4516","LU1430594728.SGD","LU2324357040.USD","LU2461242641.AUD","LU0006306889.USD","LU0965509101.SGD","IE00BN8TJ469.HKD","LU2023250504.SGD","LU2361044949.HKD","BK4007","LU0985320562.USD","LU2468319806.SGD","LU0861579265.USD","SG9999015341.SGD","LU2112291526.USD","MRK","LU1066051811.HKD","SGXZ57979304.SGD","LU2361045086.USD","IE000M9KFDE8.USD","IE00BJJMRZ35.SGD","BK4550","LU2023250843.SGD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.kerostx.com","stockEarnings":[{"period":"1week","weight":-0.0956},{"period":"1month","weight":-0.6854},{"period":"3month","weight":-0.6948},{"period":"6month","weight":-0.6333},{"period":"1year","weight":-0.5314},{"period":"ytd","weight":-0.5717}],"compareEarnings":[{"period":"1week","weight":-0.0221},{"period":"1month","weight":0.0006},{"period":"3month","weight":0.0397},{"period":"6month","weight":0.0851},{"period":"1year","weight":0.2499},{"period":"ytd","weight":0.243}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Keros Therapeutics, Inc.最初于2015年12月根据特拉华州法律注册成立。该公司是一家临床阶段生物制药公司，专注于为血液学和肌肉骨骼疾病患者开发和商业化新型治疗方法。该公司在了解转化生长因子β（一种蛋白质家族）的作用方面处于领先地位，它是红细胞和血小板生产以及肌肉和骨骼生长、修复和维护的主要调节者。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.053332},{"month":2,"riseRate":0.75,"avgChangeRate":0.108403},{"month":3,"riseRate":0.25,"avgChangeRate":-0.066035},{"month":4,"riseRate":0.25,"avgChangeRate":-0.044825},{"month":5,"riseRate":0.2,"avgChangeRate":-0.110341},{"month":6,"riseRate":0.2,"avgChangeRate":-0.056883},{"month":7,"riseRate":0.6,"avgChangeRate":0.004645},{"month":8,"riseRate":0.4,"avgChangeRate":0.085411},{"month":9,"riseRate":0.6,"avgChangeRate":0.029696},{"month":10,"riseRate":0.6,"avgChangeRate":0.145794},{"month":11,"riseRate":0.6,"avgChangeRate":0.149022},{"month":12,"riseRate":0.4,"avgChangeRate":-0.089879}],"exchange":"NASDAQ","name":"Keros Therapeutics, Inc.","nameEN":"Keros Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Keros Therapeutics, Inc.(KROS)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Keros Therapeutics, Inc.(KROS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Keros Therapeutics, Inc.,KROS,Keros Therapeutics, Inc.股票,Keros Therapeutics, Inc.股票老虎,Keros Therapeutics, Inc.股票老虎国际,Keros Therapeutics, Inc.行情,Keros Therapeutics, Inc.股票行情,Keros Therapeutics, Inc.股价,Keros Therapeutics, Inc.股市,Keros Therapeutics, Inc.股票价格,Keros Therapeutics, Inc.股票交易,Keros Therapeutics, Inc.股票购买,Keros Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Keros Therapeutics, Inc.(KROS)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Keros Therapeutics, Inc.(KROS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}